Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
129.3 USD | -0.59% | +1.35% | +18.59% |
May. 13 | Merck: phase 3 trial in melanoma halted | CF |
May. 13 | Merck Ends Co-Formulation Arm of Keytruda High-Risk Melanoma Study | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.59% | 329B | |
+29.98% | 684B | |
+30.34% | 568B | |
-3.52% | 361B | |
+4.07% | 284B | |
+16.21% | 240B | |
+9.66% | 208B | |
-6.83% | 200B | |
+7.09% | 166B | |
-1.22% | 159B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Merck & Co.'s Endometrial Cancer Combo Extends Progression-free Survival in Late-stage Study